Travere Therapeutics Inc (TVTX) Insider Trading
Total insider buys:
- $0.00
Total insider sells:
- $13,028,199.72
Most recent insider trade:
- Feb. 12, 2025
Most active insider trader:
- Eric M Dube
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
Feb. 12, 2025 | SVP | 5,200 | $23.53 | Sell | $122,356.00 | |
Feb. 11, 2025 | CEO | 11,375 | $24.04 | Sell | $273,455.00 | |
Feb. 11, 2025 | Insider | 3,074 | $25.00 | Sell | $76,850.00 | |
Feb. 11, 2025 | CAO | 54,244 | $25.00 | Sell | $1,356,100.00 | |
Feb. 6, 2025 | Director | 10,000 | $22.00 | Sell | $220,000.00 | |
Feb. 3, 2025 | Insider | 4,207 | $20.12 | Sell | $84,644.84 | |
Feb. 3, 2025 | SVP | 8,951 | $19.78 | Sell | $177,050.78 | |
Feb. 3, 2025 | CFO | 5,192 | $20.12 | Sell | $104,463.04 | |
Feb. 3, 2025 | CEO | 50,691 | $20.21 | Sell | $1,024,465.11 | |
Feb. 3, 2025 | CAO | 3,348 | $20.12 | Sell | $67,361.76 | |
Jan. 23, 2025 | Director | 16,000 | $20.00 | Sell | $320,000.00 | |
Jan. 22, 2025 | CFO | 865 | $18.94 | Sell | $16,383.10 | |
Jan. 22, 2025 | CEO | 10,736 | $19.46 | Sell | $208,922.56 | |
Jan. 22, 2025 | Insider | 1,584 | $18.94 | Sell | $30,000.96 | |
Jan. 22, 2025 | CAO | 925 | $18.94 | Sell | $17,519.50 | |
Jan. 22, 2025 | SVP | 2,437 | $19.46 | Sell | $47,424.02 | |
Jan. 6, 2025 | Insider | 440 | $18.76 | Sell | $8,254.40 | |
Jan. 3, 2025 | Insider | 2,066 | $19.10 | Sell | $39,460.60 | |
Dec. 26, 2024 | CAO | 15,000 | $17.22 | Sell | $258,300.00 | |
Nov. 25, 2024 | CAO | 12,090 | $18.30 | Sell | $221,247.00 | |
Oct. 4, 2024 | Director | 40,000 | $14.73 | Sell | $589,200.00 | |
Sept. 30, 2024 | Director | 40,000 | $14.06 | Sell | $562,400.00 | |
Sept. 9, 2024 | SVP | 4,387 | $11.52 | Sell | $50,538.24 | |
Sept. 9, 2024 | CFO | 2,490 | $11.52 | Sell | $28,684.80 | |
Sept. 9, 2024 | CEO | 21,125 | $11.52 | Sell | $243,360.00 | |
Sept. 9, 2024 | Insider | 2,191 | $11.52 | Sell | $25,240.32 | |
Sept. 4, 2024 | CFO | 514 | $9.51 | Sell | $4,888.14 | |
April 11, 2024 | CFO | 54 | $6.74 | Sell | $363.96 | |
Feb. 1, 2024 | Insider | 4,195 | $8.53 | Sell | $35,783.35 | |
Feb. 1, 2024 | CEO | 19,122 | $8.70 | Sell | $166,361.40 | |
Feb. 1, 2024 | SVP | 4,764 | $8.71 | Sell | $41,494.44 | |
Feb. 1, 2024 | CFO | 3,818 | $8.53 | Sell | $32,567.54 | |
Feb. 1, 2024 | CAO | 2,820 | $8.53 | Sell | $24,054.60 | |
Jan. 23, 2024 | SVP | 2,062 | $8.96 | Sell | $18,475.52 | |
Jan. 23, 2024 | CAO | 910 | $9.07 | Sell | $8,253.70 | |
Jan. 23, 2024 | Insider | 1,559 | $9.07 | Sell | $14,140.13 | |
Jan. 23, 2024 | CEO | 7,873 | $8.96 | Sell | $70,542.08 | |
Jan. 23, 2024 | CFO | 853 | $9.07 | Sell | $7,736.71 | |
Jan. 3, 2024 | Insider | 2,069 | $9.48 | Sell | $19,614.12 | |
Oct. 3, 2023 | Insider | 3,091 | $8.25 | Sell | $25,500.75 | |
Sept. 5, 2023 | CEO | 4,455 | $14.71 | Sell | $65,533.05 | |
Sept. 5, 2023 | SVP | 1,815 | $14.71 | Sell | $26,698.65 | |
Sept. 5, 2023 | CFO | 457 | $14.71 | Sell | $6,722.47 | |
May 10, 2023 | SVP | 825 | $16.59 | Sell | $13,686.75 | |
May 10, 2023 | CAO | 436 | $16.59 | Sell | $7,233.24 | |
May 10, 2023 | CFO | 455 | $16.59 | Sell | $7,548.45 | |
April 11, 2023 | CFO | 47 | $21.49 | Sell | $1,010.03 | |
Feb. 1, 2023 | CFO | 1,588 | $21.75 | Sell | $34,539.00 | |
Feb. 1, 2023 | CEO | 8,196 | $22.25 | Sell | $182,361.00 | |
Feb. 1, 2023 | Insider | 1,779 | $21.75 | Sell | $38,693.25 |
Insiders are selling Travere Therapeutics Inc stock.
The insider traders at Travere Therapeutics Inc are: Eric M Dube, Sandra Calvin, Christopher R Cline, William E Rote, Peter Heerma, Jula Inrig, Elizabeth E Reed, Steve Aselage, Laura Clague, Roy D Baynes, Noah L. Rosenberg, Jeffrey A Meckler, Gary A Lyons, and Noah L Rosenberg
The most active insider trader at Travere Therapeutics Inc is Eric M Dube with 16 trades.
Steve Aselage has sold the most Travere Therapeutics Inc stock with a total value of $3,633,518.88.
The most recent insider trade for Travere Therapeutics Inc was on Feb. 12, 2025.
The single biggest insider sell for Travere Therapeutics Inc was from Steve Aselage with a total value of $1,575,000.00 on Oct. 7, 2021.